Evidence map›Paper›PMID 32043070›Full record

ArticleInternational journal of reproductive biomedicine2019

Effect of oral Utrogestan in comparison with Cetrotide on preventing luteinizing hormone surge in IVF cycles: A randomized controlled trial.

Alieh Ghasemzadeh, Masumeh Dopour Faliz, Laya Farzadi, Nazli Navali, Behzad Bahramzadeh, Arash Fadavi, Parvin Hakimi, Sepideh Tehrani-Ghadim, Sedigheh Abdollahi Fard, Kobra Hamdi

Abstract read
In one paragraph

Article in International journal of reproductive biomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Progestogen-primed ovarian stimulation vs GnRH antagonists and/or agonists for women undergoing assisted reproduction: systematic review and meta-analysis.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alieh GhasemzadehWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Masumeh Dopour FalizWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Laya FarzadiWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Nazli NavaliWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad BahramzadehWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Arash FadaviWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Parvin HakimiWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sepideh Tehrani-GhadimWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sedigheh Abdollahi FardWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Kobra HamdiWomen's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral progesterone is recommended as an alternative to gonadotropin-releasing hormone (GnRH) agonists and antagonists to prevent luteinizing hormone (LH) surge in assisted reproductive technology (ART) cycles. However, there are little data regarding its use.

objectiveWe aimed to compare the effect of oral Utrogestan and Cetrotide (a GnRH antagonist) on preventing LH surge in ART cycles. MATERIALS AND

methodsIn this randomized clinical trial, 100 infertile women undergoing ART who received recombinant follicle-stimulating hormone (FSH) at 150-225 IU/day were randomly assigned to receive either Utrogestan 100 mg twice a day (case group) or GnRH antagonist protocol (control group) from cycle day 3 until the trigger day. Triggering was performed with 10,000 IU hCG) when there were at least three mature follicles. Viable embryos were cryopreserved for transfer in the next cycle for both groups. The number of oocytes retrieved and transferred embryos were compared between groups.

resultsThe case group had significantly higher progesterone levels on triggering day, more follicles of

conclusionUtrogestan is an alternative treatment that could reduce the LH surge rate and increase the ART outcomes including the number of oocytes retrieved and transferred embryos compared with GnRH agonists and antagonists.

Indexed as

In vitro fertilizationPremature luteinizationUtrogestan.

Identifiers

PMID32043070
PMCPMC6996128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.